Uterine Sarcoma Market Report 2026

The uterine sarcoma market size has grown strongly in recent years. It will grow from $2.8 billion in 2025 to $2.98 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to improved cancer diagnostic capabilities, expansion of oncology treatment centers, increased awareness of rare gynecologic cancers, availability of surgical treatment options, growth of academic oncology research.

The uterine sarcoma market size is expected to see strong growth in the next few years. It will grow to $3.78 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to increasing adoption of precision oncology treatments, rising investment in rare cancer research, expansion of targeted drug development, growing use of molecular diagnostics, increasing collaboration in oncology clinical trials. Major trends in the forecast period include increasing focus on early and accurate diagnosis, growing adoption of multimodal treatment approaches, rising use of advanced imaging and molecular testing, expansion of targeted and personalized therapies, enhanced integration of oncology care pathways.

The advancement of personalized medicine is expected to drive the growth of the uterine sarcoma market in the coming years. Personalized medicine is a healthcare approach that tailors treatments and medical decisions based on an individual’s genetic, environmental, and lifestyle factors. Its adoption is increasing due to progress in genomics, molecular profiling, and precision technologies, which enable therapies that improve effectiveness while reducing side effects. Uterine sarcoma serves as a key area for personalized medicine by providing opportunities to develop targeted approaches that leverage unique genetic and molecular insights for optimized diagnosis, treatment, and patient care. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, a significant increase from six approvals in 2022. Therefore, the growth of personalized medicine is driving expansion in the uterine sarcoma market.

Rising healthcare expenditure is expected to support the growth of the uterine sarcoma market going forward. Healthcare expenditure encompasses the total financial resources spent on medical services, treatments, infrastructure, and health-related programs. Increases in healthcare spending are driven by factors such as an aging population, higher prevalence of chronic diseases, advancements in medical technology, and growing demand for quality healthcare services. Uterine sarcoma benefits from increased healthcare spending through greater investment in advanced diagnostic tools, innovative treatments, and research initiatives, leading to better patient outcomes and improved quality of care. For example, in June 2025, the Centers for Medicare and Medicaid Services (CMS), a US-based federal health data authority, reported that US healthcare spending grew by 7.5% in 2023, reaching $4.9 trillion - or $14,570 per person - accounting for 17.6% of the nation’s GDP. Therefore, rising healthcare expenditure is driving the growth of the uterine sarcoma market.

The increasing adoption of minimally invasive surgeries is expected to propel the growth of the uterine sarcoma market in the coming years. Minimally invasive surgeries are procedures performed through small incisions using specialized instruments, often including laparoscopic or robotic-assisted techniques, which reduce recovery time and minimize tissue damage. These procedures are gaining popularity because patients prefer treatments that cause less pain, shorten hospital stays, and allow a faster return to daily activities. Minimally invasive surgeries enhance uterine sarcoma treatment by enabling surgeons to precisely remove tumors through smaller incisions, reducing trauma to surrounding tissues, accelerating patient recovery, and allowing earlier postoperative interventions. For example, in January 2025, Intuitive Surgical, Inc., a US-based biotechnology company, reported that in 2024, nearly 2.7 million procedures were performed using its products, a 17% increase from 2023, bringing cumulative experience on da Vinci platforms to almost 17 million procedures. During the year, the company placed 1,430 da Vinci multiport systems, 271 Ion systems, and 96 da Vinci SP systems. Therefore, the growing popularity of minimally invasive surgeries is driving the uterine sarcoma market.

Major companies operating in the uterine sarcoma market are Merck And Co. Inc., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Incyte Corporation, Karyopharm Therapeutics Inc., Bayer AG, Nanobiotix, Iovance Biotherapeutics, Mirati Therapeutics, CytRx, Taiho Pharmaceuticals, Advenchen Laboratories, Philogen, Gradalis, Apexigen, Lytix Biopharma, Aadi Bioscience, AVEO Pharmaceuticals, VasGene Therapeutics, ImmunityBio.

North America was the largest region in the uterine sarcoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the uterine sarcoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the uterine sarcoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the uterine sarcoma market by increasing costs of imported diagnostic imaging systems, biopsy tools, oncology drugs, laboratory reagents, and radiation therapy equipment. Hospitals and research institutions in North America and Europe are most affected due to reliance on imported oncology technologies, while Asia-Pacific faces cost pressures on pharmaceutical imports. These tariffs are increasing treatment expenses and research costs. However, they are also supporting domestic drug manufacturing, regional oncology research expansion, and localized production of diagnostic equipment.

The uterine sarcoma market research report is one of a series of new reports that provides uterine sarcoma market statistics, including uterine sarcoma industry global market size, regional shares, competitors with a uterine sarcoma market share, detailed uterine sarcoma market segments, market trends and opportunities, and any further data you may need to thrive in the uterine sarcoma industry. This uterine sarcoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Uterine sarcoma is a rare and aggressive cancer that arises in the smooth muscle or connective tissue of the uterus, unlike the more common endometrial cancer, which develops in the uterine lining. This cancer is known for its rapid growth and potential to spread to other parts of the body, making early detection and intervention critical for improving treatment outcomes. Uterine sarcomas are usually diagnosed through imaging tests, biopsy, and histological analysis.

The main types of uterine sarcoma include uterine leiomyosarcoma, undifferentiated sarcoma, endometrial stromal sarcoma, and other forms. Uterine leiomyosarcoma is a rare, aggressive cancer originating from the smooth muscle of the uterus, noted for high recurrence rates and poor prognosis. Diagnosis involves methods such as tissue sampling and testing, imaging, and other diagnostic techniques. Treatment options include surgery, radiation therapy, hormone therapy, chemotherapy, and other approaches. Management of the disease is carried out by end users such as hospitals, clinics, academic institutions, research organizations, and other healthcare providers.

The uterine sarcoma market consists of sales of radiation therapy equipment, hormone therapy drugs, prosthetics and reconstructive surgery products, and immuno-oncology products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.